Data Characteristics for This Category
Pharmacoeconomics data primarily originates from clinical research reports, real-world evidence (RWE) databases, national medical insurance catalogs, drug pricing policy documents, and medical literature. This data updates frequently, with new clinical trial results and policy adjustments released regularly. Document structures typically include detailed trial designs, patient cohort characteristics, drug intervention protocols, cost-effectiveness analysis models, outcome measures (e.g., QALY, ICER values), and sensitivity analyses. Fields cover disease burden, treatment costs (direct and indirect), treatment effectiveness indicators, and health outcome measurement tools (e.g., EQ-5D scores). Units involve currency (e.g., USD, EUR, RMB), time (e.g., years, months), Quality-Adjusted Life Years (QALY), and Incremental Cost-Effectiveness Ratios (ICER).
Constraints Imposed by These Characteristics on Knowledge Base Retrieval and Recall
The high update frequency of pharmacoeconomics data necessitates efficient incremental update and version management capabilities in the knowledge base to ensure timely retrieval results. Complex document structures and diverse fields and units require careful attention to semantic integrity during chunking. This prevents the disconnection of critical economic indicators or conclusions due to segmentation. For instance, an ICER value is meaningful only when combined with its calculation method, the intervention measures being compared, and the scope of sensitivity analysis. Precise retrieval of specific indicators, such as "the QALY value of a certain drug for a certain indication," requires the knowledge base to accurately identify and recall text segments containing these specific fields and units. Furthermore, due to dispersed and varied data sources, the knowledge base must handle multiple file types during data ingestion and perform effective structured or semi-structured information extraction.
Configuration Guidelines
| Configuration Item | Recommended Value | Rationale |
|---|---|---|
Chunk size (Chunk Length) | 300–500 characters (characters) | Ensures each text chunk contains a complete pharmacoeconomic conclusion or key indicator, preventing semantic loss. |
Chunk Overlap Length (Chunk Overlap Length) | 50 characters (characters) | Maintains contextual coherence, aiding in the understanding of economic arguments across segments. |
Recall count (Recall Count) | Top 8 entries (top 8) | Given the complexity of pharmacoeconomic analysis, increasing the recall quantity covers more relevant arguments. |
Similarity threshold (Similarity Threshold) | 0.75 | Balances accuracy and recall rate, filtering for highly relevant economic data. |
Rerank result count (Rerank Return Count) | Top 3 entries (top 3) | Further improves the ranking of the most relevant results after initial recall. |
Maximum Chunk Count | 2000 | Accommodates the extensive analytical details often found in a single pharmacoeconomic report. |
Common Pitfalls
- After importing PDF documents into the knowledge base, question-answering accuracy is low. This occurs because tables, charts, or complex layouts within
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.